18-Sept-2026 10:22:37

CONCORD BIOTECH : USFDA INSPECTION AT UNIT II CONCLUDED WITH MINOR OBSERVATION

• USFDA conducted an inspection at the company's Unit II-Valthera formulation facility. • The inspection was successfully concluded on September 18, 2026. • USFDA issued one minor procedural observation, not related to GMP. • Company will submit a comprehensive response within the stipulated timeline. • No material impact expected on current business operations or supplies. Impact: Neutral (Procedural observation not related to GMP, no expected business impact)

Concord Biotech Ltd

← Back to feed